Ocean Biomedical, Inc. (OCEA)
收市後：
| 前收市價 | 1.4000 |
| 開市 | 1.3900 |
| 買盤 | 1.4500 x 100 |
| 賣出價 | 1.5000 x 100 |
| 今日波幅 | 1.3900 - 1.4900 |
| 52 週波幅 | 0.5200 - 12.0800 |
| 成交量 | |
| 平均成交量 | 7,174,226 |
| 市值 | 50.934M |
| Beta 值 (5 年，每月) | 1.30 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.0000 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 18.50 |
Insider Monkey13 Hot Stocks to Invest in According to Wall Street Analysts
In this piece, we will take a look at the 13 hot stocks to invest in according to Wall Street analysts. If you want to skip our overview of the stock market and the latest news, then you can skip ahead to the 5 Hot Stocks to Invest in According to Wall Street Analysts. Just […]
BenzingaEXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody
Ocean Biomedical (NASDAQ: OCEA) announced that its Scientific Co-founder, Jack Elias, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple-negative breast cancer. The research demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs, which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact o
BenzingaEXCLUSIVE: Ocean Biomedical's JV Partner Virion Therapeutics Dosed First Patients In Novel Immunotherapy Study For Chronic Hepatitis B
Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that its joint venture partner, Virion Therapeutics, has dosed its first patient in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy. Virion Therapeutics is a clinical-stage biotechnology company developing novel T cell-based immunotherapies. VRON-0200 immunotherapy is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection. VRON-0200, a pioneering therapy, leverages Virion's propri
